Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102388 | 0.92 | ALDH1A1 (0.61) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL13102109 | 0.87 | LMNA (0.43) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL15037549 | 0.87 | NPSR1 (0.41) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL3378112 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL13102264 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL13101709 | 0.85 | MEN1 (0.44) | ALDH1A1KMT2AHTTMEN1L3MBTL1 | |
| SCHEMBL13102241 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL3381133 | 0.84 | RAB9A (0.48) | ALDH1A1KMT2AHTTLMNAMEN1 | |
| SCHEMBL13102314 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL13102069 | 0.83 | NPSR1 (0.41) | ALDH1A1HTTL3MBTL1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885KMT2A 1295/4885HTT 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.